Is FBT a good investment?

First Trust NYSE Arca Biotechnology Index Fund (FBT) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores FBT 4.6 out of 10 — highest on Growth (5.4), lowest on Quality (3.2). It trades at 23.8 times earnings, against its own median of 23.6. Its ten largest holdings are 38% of the fund.

Updated September 11, 2026

How is FBT rated? ETF Copilot scores First Trust NYSE Arca Biotechnology Index Fund (FBT) 4.6 out of 10

As of September 11, 2026, ETF Copilot scores First Trust NYSE Arca Biotechnology Index Fund (FBT) 4.6 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 4.6 / 10
Growth: 5.4 / 10
Valuation: 4.0 / 10
Risk: 4.1 / 10
Quality: 3.2 / 10
Return: 5.4 / 10

What is FBT's expense ratio? 0.55% a year

As of September 11, 2026, FBT charges 0.55% a year, yields 0.23% and holds $2.9B in assets across 30 positions.

First Trust NYSE Arca Biotechnology Index Fund (FBT) — cost, income and size
Measure	FBT
Expense ratio	0.55%
Dividend yield	0.23%
Assets under management	$2.9B
Holdings	30

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in FBT's data

Tracks U.S. biotechnology sector companies focused on innovation and growth.

Priced at a steep premium to the typical biotech fund — you pay more for each dollar of earnings.

Its trailing EBITDA multiple of 21.5x is among the priciest in the category, well above the peer median of 15.9x. The fund's EBITDA margin of 21.3% sits below average, and it pays a negligible dividend of 0.2%.

Adds a high-valuation biotech tilt to a portfolio already holding broader technology exposure.

Why did FBT move this week? It fell 4.4% in the week to September 11, 2026 — Amgen and Sarepta Therapeutics drove it

FBT fell 4.4% in the week to September 11, 2026. The holdings that moved it most were Amgen (−15.0%), Sarepta Therapeutics (−11.0%) and Bruker (−10.1%); Axsome Therapeutics (+6.0%) pushed the other way.

Is FBT expensive right now? It trades at 23.8 times earnings, against its own median of 23.6

As of September 11, 2026, FBT is more expensive than 51% of its own 114 monthly readings since 2017 — 58 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside FBT?

What's inside FBT: Size (Large 34%, Mid 53%, Small 13%); Geography (International 17%, US 83%).

What are FBT's top holdings? The ten largest are 38% of the fund

Halozyme Therapeutics, Corcept Therapeutics, Neogenomics, Natera, Regeneron Pharmaceuticals, Beone Medicines, Repligen, Argenx SE, Gilead Sciences and Genmab A/S are FBT's largest holdings, in that order.

Less concentrated than 56% of Healthcare & Biotech ETFs.

Half of FBT's weight sits in its 14 largest positions, and once those weights are taken into account it behaves like 30 equally weighted holdings.

Cite this

ETF Copilot, “First Trust NYSE Arca Biotechnology Index Fund (FBT) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/fbt